Linzess (linaclotide) - Ironwood Pharma, AbbVie
Efficacy, Safety, and Tolerability of Bowel Preparation Regimens in Elderly Adults: A Systematic Review and Network Meta-Analysis (ACG 2026) - Aug 29, 2026 - Abstract #P5377; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "Eighteen RCTs (13 regimens) were included from 6,028 records. The only significant comparison, 1L PEG-Asc + linaclotide versus 2L PEG-Asc (OR 3.82, 95% CI 1.22-11.93), was an indirect estimate whose linaclotide node rests on a single low-certainty trial. I²=0% with no inconsistency detected, though sparse data limit power to detect either." 
Retrospective data • Review
https://acg2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=R01PT1FGR0UyNjkyNQ&PosterID=827145&rnd=0.2376172
 
Het G. Patel; BBMed; Christopher Leung; MBBS; FRACP; PhD; PostGradDipClinEd; Neville D. Yeomans; MD; PhD
 
Aug 29, 2026
 
Prev Next